Unum Therapeutics Inc. (UMRX): Price and Financial Metrics


Unum Therapeutics Inc. (UMRX)

Today's Latest Price: $2.35 USD

0.01 (0.43%)

Updated Oct 5 12:00am

Add UMRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

UMRX Stock Summary

  • Unum Therapeutics Inc's stock had its IPO on March 29, 2018, making it an older stock than only 6.84% of US equities in our set.
  • As for revenue growth, note that UMRX's revenue has grown 98.25% over the past 12 months; that beats the revenue growth of 94.68% of US companies in our set.
  • In terms of volatility of its share price, UMRX is more volatile than 98.3% of stocks we're observing.
  • Stocks that are quantitatively similar to UMRX, based on their financial statements, market capitalization, and price volatility, are PIRS, CDTX, SYBX, NXTC, and KALV.
  • Visit UMRX's SEC page to see the company's official filings. To visit the company's web site, go to www.unumrx.com.

UMRX Stock Price Chart Interactive Chart >

Price chart for UMRX

UMRX Price/Volume Stats

Current price $2.35 52-week high $3.72
Prev. close $2.34 52-week low $0.29
Day low $2.32 Volume 124,600
Day high $2.41 Avg. volume 1,222,692
50-day MA $2.60 Dividend yield N/A
200-day MA $1.26 Market Cap 99.80M

Unum Therapeutics Inc. (UMRX) Company Bio


Unum Therapeutics Inc., a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. Its lead product candidate is the ACTR087 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory non-Hodgkin lymphoma. The company’s product portfolio also includes ACTR707 used in combination with rituximab that is in Phase I clinical trials to treat adult patients with r/r B cell non-Hodgkin lymphoma; ACTR087 used in combination with SEA-BCMA, which is in Phase I clinical trials for treating patients with r/r multiple myeloma; and ACTR707 used in combination with trastuzumab, which is in late preclinical development phase for treating HER2+ solid tumor cancers. It has strategic collaboration with Seattle Genetics, Inc. to identify, research, develop, and commercialize antibody-coupled T cell receptor therapies. The company was founded in 2014 and is based in Cambridge, Massachusetts.


UMRX Latest News Stream


Event/Time News Detail
Loading, please wait...

UMRX Latest Social Stream


Loading social stream, please wait...

View Full UMRX Social Stream

Latest UMRX News From Around the Web

Below are the latest news stories about Unum Therapeutics Inc that investors may wish to consider to help them evaluate UMRX as an investment opportunity.

Venrock Healthcare Capital Partners acquires 0.451M shares of Unum Therapeutics

Venrock Healthcare Capital Partners discloses the purchase 0.451M shares of Unum Therapeutics (UMRX) between Aug. 14 and Aug. 18 at average price of $2.52/share.Shares +9% premarket....

Seeking Alpha | August 19, 2020

Unum Therapeutics reports Q2 results

Unum Therapeutics (UMRX): Q2 GAAP EPS of -$0.24.Revenue of $0.53M (-83.1% Y/Y)Shares -2.8% AH.Press Release...

Seeking Alpha | August 11, 2020

Kaskela Law LLC Announces Investigation of Unum Therapeutics Inc. and Encourages Long-Term Investors to Contact the Firm - UMRX

Kaskela Law LLC announces that it is investigating Unum Therapeutics Inc. (NASDAQ: UMRX) ("Unum" or the "Company") on behalf of the Company's investors.

Yahoo | July 21, 2020

Top Ranked Momentum Stocks to Buy for July 17th

Top Ranked Momentum Stocks to Buy for July 17th

Yahoo | July 17, 2020

Unum Therapeutics Inc. (UMRX) Shares March Higher, Can It Continue?

As of late, it has definitely been a great time to be an investor in Unum Therapeutics Inc. (UMRX).

Yahoo | July 9, 2020

Read More 'UMRX' Stories Here

UMRX Price Returns

1-mo N/A
3-mo -17.83%
6-mo 328.91%
1-year 219.51%
3-year N/A
5-year N/A
YTD 226.30%
2019 -83.63%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching UMRX

Want to see what other sources are saying about Unum Therapeutics Inc's financials and stock price? Try the links below:

Unum Therapeutics Inc (UMRX) Stock Price | Nasdaq
Unum Therapeutics Inc (UMRX) Stock Quote, History and News - Yahoo Finance
Unum Therapeutics Inc (UMRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7737 seconds.